Gilead Partners with Indian Manufacturers on HIV Medicines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gilead Partners with Indian Manufacturers on HIV Medicines


ePT--the Electronic Newsletter of Pharmaceutical Technology

Gilead Sciences announced that it is entering into agreements with Mylan Laboratories, Ranbaxy Laboratories, and Strides Arcolab to enhance access in developing countries to generic versions of its anti-HIV medicine, emtricitabine. According to the press release, emtricitabine is recommended by the World Health Organization as one of the preferred components of first- and second-line HIV therapy, but is more expensive than other available therapy options. Under the agreements, Gilead will provide technology transfer to its partners for the manufacture of emtricitabine, together with funding to assist with investment in process improvements.  The aim is to reduce overall manufacturing costs, allow Indian generics manufacturers to produce high volumes of Gilead’s antiretroviral therapy, and thereby reduce the cost of emtricitabine to be more in line with that of other therapies.

Gilead says it has a longstanding commitment to make its antiretroviral products available at significantly reduced prices in developing countries. A key component of this commitment is nonexclusive, generic licensing agreements established with Indian manufacturers to produce and sell high-quality, low-cost versions of Gilead's HIV medicines. A total of 13 Indian companies now have licensed Gilead HIV medicines. According to John C. Martin, PhD, Gilead’s chairman and chief executive officer, “India’s pharmaceutical industry is a world leader in process chemistry, and our ongoing collaboration will be critical for furthering access to affordable, high-quality, first-line HIV treatment for developing countries.” 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here